Targeting IGF2BP2 in MLL‑rearranged leukemia
The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia
['FUNDING_R01'] · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · NIH-11263640
This project will look at whether blocking IGF2BP2, a protein that is high in MLL‑rearranged acute myeloid leukemia, can stop leukemia stem cells and lead to better treatments for people with this aggressive subtype.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE (nih funded) |
| Locations | 1 site (DUARTE, UNITED STATES) |
| Trial ID | NIH-11263640 on ClinicalTrials.gov |
What this research studies
Researchers will focus on a protein called IGF2BP2 that reads mRNA chemical tags and is unusually high in MLL‑rearranged AML. They will study patient samples, leukemia cell lines, and animal models to learn how IGF2BP2 helps leukemia stem cells survive and drive relapse. The team will use genetic tools and candidate drugs to block IGF2BP2 activity and observe effects on leukemia growth and stem‑cell self‑renewal. Results could identify a new way to target the root cells that cause treatment failure in MLL‑rearranged AML.
Who could benefit from this research
Good fit: People diagnosed with MLL‑rearranged acute myeloid leukemia (including therapy‑related cases) or those willing to donate blood or bone marrow samples for research would be the most relevant candidates.
Not a fit: Patients with AML who do not have MLL rearrangements or those with unrelated cancers are unlikely to receive direct benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could point to new treatments that specifically target leukemia stem cells and improve outcomes for patients with MLL‑rearranged AML.
How similar studies have performed: Laboratory studies targeting m6A regulators and their binding proteins have shown promising effects in preclinical models, but clinical benefit in patients has not yet been established.
Where this research is happening
DUARTE, UNITED STATES
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE — DUARTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, JIANJUN — BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- Study coordinator: CHEN, JIANJUN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.